Every 8-K that Advent Technologies Holdings, Inc. (ADN) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow ADN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ADN filings page.
Advent Technologies (ADN) repaid and terminated a short-term financing note. The company fully repaid a Convertible Promissory Note with an aggregate principal amount of $235,000.00 (including an original issue discount of $25,000.00) bearing 12% annual interest, originally provided by Hudson Global Ventures LLC. As of November 5, 2025, all amounts and conditions under the note were satisfied, and the note was terminated upon repayment.
The original financing also included a pre-funded warrant to purchase 130,000 shares of common stock. The filing focuses on extinguishing the debt obligation; it does not alter the described warrant terms.
Advent Technologies Holdings, Inc. announced that two directors resigned from the Board. Marc Seelenfreund resigned effective October 29, 2025, and Joseph Celia resigned effective October 30, 2025. The company stated that both resignations were not due to any disagreement with the company on matters related to operations, policies, or practices.
Advent Technologies Holdings, Inc. reported it received a notice from Nasdaq that the exchange will commence proceedings to delist its common stock and public warrants for failure to comply with Nasdaq Listing Rule 5550(b)(1). Trading in both securities will be suspended effective October 30, 2025.
Nasdaq will apply to the SEC to complete the delisting process. The company’s common stock is expected to continue trading on the OTC market under the symbol ADN, and its public warrants are expected to trade on the OTC under ADNWW.
Advent Technologies Holdings (ADN) reported results from its October 22, 2025 annual meeting. Stockholders elected Class II directors Marc Seelenfreund (878,371 for) and Seth Lukash (898,871 for), and Joseph Celia (900,171 for). They ratified M&K CPAS, PLLC as auditor with 1,161,826 votes for.
Shareholders approved a Nasdaq Listing Rule 5635(d) item permitting the potential issuance and sale of 20% or more of common stock under a purchase agreement with Hudson Global Ventures, LLC, under which Hudson Global may purchase up to $52,000,000 of common stock from time to time. They also approved an amendment to the 2021 Incentive Plan, increasing shares issuable from 530,976 to 1,011,627 and adding an annual increase beginning January 1, 2027 through January 1, 2046, equal to the lesser of 3% of shares outstanding at the prior fiscal year-end or a smaller number set by the Board.
Stockholders approved the advisory say-on-pay (829,029 for) and indicated a preference on say-on-pay frequency, with 559,297 votes for every three years. As of September 19, 2025, shares outstanding were 3,291,634, and 1,307,771 shares were represented at the meeting.
Advent Technologies Holdings, Inc. filed an 8-K reporting a material transaction: the company entered into a Securities Purchase Agreement dated August 28, 2025 with investors and issued a Common Stock Purchase Pre‑Funded Warrant dated August 28, 2025 in favor of Hudson Global Ventures, LLC. The filing identifies the agreements as exhibits (10.1 and 10.2) and is signed by Chief Executive Officer Gary Herman. The notice indicates a capital markets transaction occurred but does not disclose economic terms, share counts, or proceeds in the provided text.
Advent Technologies Holdings, Inc. received a Nasdaq delisting determination after failing to restore stockholders’ equity to the level required by Nasdaq Listing Rule 5550(b)(1), which calls for at least $2,500,000 of stockholders’ equity for continued listing. Nasdaq had previously given the company until April 16, 2025 to regain compliance and later deemed it in conditional compliance, expecting the necessary equity adjustment to be reflected in the Form 10-Q for the quarter ended June 30, 2025.
The Form 10-Q filed on August 12, 2025 did not show a sufficient equity adjustment, and on August 18, 2025 Nasdaq issued a notice stating that Advent’s securities would be delisted on August 27, 2025 unless the company requested a hearing by August 25, 2025. Advent intends to appeal this determination to a Nasdaq hearings panel, which would stay any further delisting actions during the appeal process, and its common stock (symbol ADN) and warrants (symbol ADNWW) are expected to continue trading on Nasdaq while the appeal is pending.
Advent Technologies Holdings, Inc. filed an 8-K reporting the entry into a material definitive agreement and an unregistered sale of equity securities. The filing lists a Registration Rights Agreement dated August 14, 2025 between the company and Hudson as an exhibit. The document identifies the event categories but provides no transaction economics, share counts, or pricing in the excerpt provided. The form is signed on behalf of the company by Gary Herman, Chief Executive Officer.
The disclosure signals a financing or equity transfer tied to registration rights for the purchaser, which can affect share liquidity and potential dilution depending on the omitted terms. Key transactional details required to judge material financial impact (amounts, number of shares, use of proceeds, and effective dates beyond the exhibit date) are not present in the supplied text.
Advent Technologies Holdings, Inc. filed a Form 8-K reporting that its wholly-owned subsidiary, Advent Technologies, Inc., finalized a partially exclusive field-of-use patent license with TRIAD National Security for the Ion Pair technology originally developed at Los Alamos National Laboratory. The Agreement, which supersedes a prior license between the parties, grants Advent Sub exclusivity in the marine, aviation, and portable power fields while Advent Sub retains non-exclusive rights in all other fields.
The filing attaches the press release as Exhibit 99.1 and a cover page interactive data file as Exhibit 104, and is signed by CEO Gary Herman on August 12, 2025. The document does not disclose financial terms, duration, or other commercial details of the Agreement.